Lebsa

What Lebsa does

Lebsa (legally Laboratorios Espinos y Bofill SA) is a privately held pharmaceutical manufacturer founded in 1951 by Dr. Josep Maria Espinós and headquartered in Cornellà de Llobregat, Barcelona, Spain. The company synthesizes, manufactures, and commercializes Active Pharmaceutical Ingredients (APIs), focused explicitly on niche and tailor-made molecules rather than commodity APIs, with a current standard portfolio of 16 molecules including Dequalinium Chloride, Mianserin Hydrochloride, Bromopride, Sulpiride, Amisulpride, Betahistine salts, Venetoclax, and several antiseptic agents such as Picloxidine, Propamidine, Dibrompropamidine, and Octenidine dihydrochlorides. Core technical capabilities center on continuous flow chemistry using micro and meso-scale reactors, an in-house GMP Pilot Plant for scale-up from R&D to commercial production, a published HarsMeth safety methodology for batch and semi-batch hazard assessment, and advanced laboratory instrumentation (Corning Low-Flow, Biotage microwave, Waters UHPLC with mass detector, Agilent HPLC).

The business serves B2B pharmaceutical customers across three target segments: pharmaceutical companies requiring APIs for branded or generic formulations (primary), FDF manufacturers seeking alternative API sources (secondary), and traders (secondary). Revenue is generated through quote-based, per-kilogram supply contracts of proprietary APIs with bundled regulatory documentation including EU DMF/ASMF in CTD format and CEP filings supported across EMA, PMDA, ANVISA, TGA, MIT Rusia, Taiwan FDA, China NMPA, and Health Canada. Pricing is not publicly disclosed and orders are captured through website inquiry forms specifying kg/year requirements. Lebsa holds CEPs from EDQM, ISO 14001 and ISO 45001 certifications from AENOR, and a 2022 Gold EcoVadis Medal.

Go-to-market is enterprise field sales augmented by content marketing (company blog on flow chemistry, sustainability, process safety), an active LinkedIn presence, a YouTube channel, and participation in pharmaceutical industry events such as CPHI Barcelona and the Mediterranean Congress of Chemical Engineering. Distribution operates through a single HQ manufacturing site in Cornellà, supported by channel partnerships (Selectchemie at CPHI) and research collaborations (PHARO with Leitat on circular-economy water regeneration). The company is independently owned with no disclosed venture or private equity backing, and operates with a 2020-expanded 3,000+ sqm facility housing R&D, QC, offices, and warehousing, with R&D representing approximately 18% of total headcount.

Name

Lebsa

Legal name

LABORATORIOS ESPINOS Y BOFILL SA

Website

https://lebsa.com

Company type

Private

Founded year

1951

Operating status

Operating

Headcount range

11–50 employees

Short description

Lebsa is a privately held, Barcelona-based Active Pharmaceutical Ingredient manufacturer founded in 1951, focused on niche and tailor-made APIs supplied globally to pharmaceutical companies, FDF manufacturers, and traders with bundled regulatory documentation.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (API) Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Active pharmaceutical ingredients
• API manufacturing services
• Niche molecule APIs
• GMP certified production
• Flow chemistry manufacturing

Headquarters

HQ city

Cornellá De Llobregat

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (API) Manufacturing: LEBSA manufactures and supplies niche and tailor-made Active Pharmaceutical Ingredients to pharmaceutical companies globally. Revenue is generated through the sale of proprietary APIs with full quality control and regulatory management.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Lebsa (Laboratorios Espinos y Bofill SA) manufactures and commercializes niche and tailor-made Active Pharmaceutical Ingredients (APIs) from its GMP-certified facilities in Barcelona, Spain. The company produces 16 standard APIs across therapeutic categories including antidepressants, antipsychotics, antiseptics, and antivertigo compounds, and supports clients with regulatory documentation (EU DMF/ASMF in CTD format, CEP) for registration with EMA, PMDA, ANVISA, TGA, and other global agencies. Complementary offerings include a GMP pilot plant for scale-up and flow-chemistry-based R&D services.

Product overview

Lebsa is a European API (Active Pharmaceutical Ingredients) manufacturer based in Barcelona, Spain, operating since 1951. The company offers a portfolio of 16 standard niche molecule APIs including Dequalinium Chloride, Picloxidine Dihydrochloride, Bromopride, Propamidine Isetionate, Dibrompropamidine Isetionate, Histamine Dihydrochloride, Octenidine Dihydrochloride, Venetoclax, Lacidipine, Sulpiride, Histamine Diphosphate Monohydrate, Amisulpride, Betahistine Dihydrochloride, Betahistine Dimesilate, Mianserin Hydrochloride, and Tiapride Hydrochloride. The company also maintains an R&D pipeline with products like Letermovir. In addition to API manufacturing, Lebsa provides regulatory support services including EU DMF/ASMF in CTD format and CEP documentation, GMP pilot plant services, and EHS (Environmental, Health & Safety) compliance support. The company operates its own GMP-certified facilities giving complete control over operations and production management.

Differentiator

Problem solved

Functional benefit

Products and services

• Dequalinium Chloride An antiseptic and disinfectant Active Pharmaceutical Ingredient with topical antimicrobial properties, used to treat mouth infections, wound dressings, and local vaginal infections such as vulvo-vaginal candidiasis, bacterial vaginosis, and trichomoniasis. Manufactured in Lebsa's GMP-certified facility in Barcelona, Spain.
• Picloxidine Dihydrochloride An antiseptic agent API used in topical applications for antimicrobial purposes, included in Lebsa's standard product portfolio and manufactured at the Barcelona GMP facility.
• Bromopride A pharmaceutical Active Pharmaceutical Ingredient included in Lebsa's standard API portfolio, manufactured at the GMP-certified Barcelona facility.
• Propamidine Isetionate An antiseptic agent API for topical use in pharmaceutical applications, part of Lebsa's standard product portfolio.
• Dibrompropamidine Isetionate A disinfectant and antiseptic API used in topical pharmaceutical preparations, included in Lebsa's standard product portfolio.
• Histamine Dihydrochloride A pharmaceutical Active Pharmaceutical Ingredient included in Lebsa's standard portfolio, manufactured under GMP at the Barcelona facility.
• Octenidine Dihydrochloride A pharmaceutical API that was the subject of a 2023 R&D development challenge for Lebsa's R&D department, focusing on new synthesis methods. Part of the standard product portfolio.
• Venetoclax A pharmaceutical Active Pharmaceutical Ingredient included in Lebsa's standard product portfolio, manufactured at the GMP-certified Barcelona facility.
• Lacidipine A pharmaceutical Active Pharmaceutical Ingredient included in Lebsa's standard product portfolio, manufactured under GMP at the Barcelona facility.
• Sulpiride A pharmaceutical Active Pharmaceutical Ingredient included in Lebsa's standard product portfolio, manufactured under GMP at the Barcelona facility.
• Histamine Diphosphate Monohydrate A pharmaceutical Active Pharmaceutical Ingredient included in Lebsa's standard product portfolio, manufactured under GMP at the Barcelona facility.
• Amisulpride A pharmaceutical Active Pharmaceutical Ingredient included in Lebsa's standard product portfolio, manufactured under GMP at the Barcelona facility.
• Betahistine Dihydrochloride A pharmaceutical Active Pharmaceutical Ingredient used for antivertigo applications, part of Lebsa's standard product portfolio.
• Betahistine Dimesilate A pharmaceutical Active Pharmaceutical Ingredient included in Lebsa's standard product portfolio, manufactured under GMP at the Barcelona facility.
• Mianserin Hydrochloride An oral antidepressant API belonging to the piperazine-azepine group of compounds, working by inhibiting norepinephrine uptake and blocking alpha-2 receptors with additional interactions with serotonin receptors. Manufactured in Lebsa's GMP plant in Barcelona.
• Tiapride Hydrochloride A pharmaceutical Active Pharmaceutical Ingredient included in Lebsa's standard product portfolio, manufactured under GMP at the Barcelona facility.
• Regulatory Support Services Comprehensive API regulatory support including EU DMF/ASMF in CTD format and/or CEP documentation, with guidance through registration processes with major regulatory agencies (EMA, PMDA, ANVISA, TGA, MIT Rusia, Taiwan FDA, China NMPA, Health Canada). Provided to pharmaceutical clients as a bundled service with API supply.
• EHS Integrated Policy Services Environmental, Health, and Safety integrated policy services ensuring compliance with health and safety standards in the pharmaceutical industry, including solid and liquid waste management, supported by ISO 14001 and ISO 45001 certifications issued by AENOR.
• GMP Pilot Plant Services One of the first GMP Pilot Plants operated by an API manufacturer, offering versatile manufacturing capabilities for pharmaceutical companies, enabling scale-up from R&D quantities to commercial production within Lebsa's own facilities.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• LeitatcoreStrategic or Co-development Partner · 18 September 2024LEBSA together with Leitat leads the PHARO project - a pioneering circular economy initiative in the pharmaceutical industry based on water regeneration. The project aims to optimize production processes of the industry and focuses on water regeneration and sustainable manufacturing practices.
• SelectchemiecoreChannel Partner/ Reseller/ DistributorLEBSA and Selectchemie joined forces at CPHI Barcelona to drive innovation in the pharmaceutical industry. The partnership involves collaboration on pharmaceutical ingredients and market development activities.
• SGSminorImplementation/ SI/ Consulting PartnerLEBSA implemented LEAN methodology along with SGS starting in 2020. SGS assisted in the LEAN project focused on achieving improvement of process management and organizational efficiency in API manufacturing.
• Mediterranean Congress of Chemical Engineering / SEQUIminorOthersLEBSA's R&D team participated in the 14th Mediterranean Congress of Chemical Engineering as lecturers, presenting on flow chemistry applications for API synthesis. The Congress is held with technical and scientific support of SEQUI, Enginyers industrials de Catalunya, and AIQS.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• ICROM: Italian API manufacturer producing niche small-molecule APIs including controlled substances for global pharma; comparable in niche small-molecule focus, GMP manufacturing, and European origin.
• Olon Group: Italy-based API CDMO with a large portfolio of generic and niche small-molecule APIs and a global regulatory footprint; comparable in niche small-molecule focus, European manufacturing, and B2B pharma sales motion.
• PharmaZell: Germany-based specialty API manufacturer focused on niche small molecules and custom synthesis; comparable to Lebsa in niche positioning, European manufacturing, and B2B pharma customer base.
• Dipharma Francis: Italian API manufacturer specializing in niche generics with GMP facilities and CEP-supported dossiers; comparable in niche small-molecule API positioning and European regulatory expertise.
• Siegfried Holding AG: Swiss small-molecule API manufacturer with global GMP facilities serving branded and generic pharma; comparable in customer base (FDF manufacturers), regulatory documentation services, and European manufacturing footprint.
• EUROAPI: French API manufacturer spun out of Sanofi, offering a broad small-molecule API portfolio with multi-jurisdiction regulatory support; comparable in API category, regulatory dossiers (CEP/DMF) and European B2B go-to-market.
• Hovione: Portugal-headquartered CDMO specializing in small-molecule API manufacturing with deep flow chemistry and particle engineering expertise — directly comparable to Lebsa in niche small-molecule APIs, technology profile, and European base.

Broad incumbents

• Recipharm: Large Swedish CDMO offering API and finished-dose services across multiple technologies; overlaps with Lebsa on small-molecule API supply but operates at much broader scale and service scope.
• Cambrex: US-headquartered small-molecule API CDMO (owned by Permira) serving global pharma; comparable in API manufacturing and regulatory support but materially larger and broader in capability than Lebsa.
• Evotec (CDMO/Aptuit): Global CDMO (via Aptuit) offering API and integrated drug substance services with strong process chemistry; comparable in process chemistry and API service capabilities, though operating at much broader scale and scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCI0zVsdSZCXNXTnSTK1SRPg
• LinkedInau.linkedin.com/company/lebsa-api-manufacturer

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lebsa